Pharmaceutical Executive

This Pharma 50 companion episode delves into the vital topic of trust within the pharmaceutical industry. Morton Nielsen, senior partner for the life sciences practice at Wittkieffer, dissects the concept, drawing on parallels to Maslow's hierarchy of needs, and discusses practical methods for measuring and operationally improving trust. This episode is a must-listen for those interested in understanding the current state and future evolution of trust in the pharmaceutical sector, an industry where trust forms a fundamental pillar for delivering on its mission statement. Read the 2023 Pharma 50 article here: https://www.pharmexec.com/view/2023-pharm-exec-top-50-companies

The 2023 Emerging Pharma Leaders share with Meg Rivers, managing editor of Pharmaceutical Executive, and the editorial team what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. Congratulations to the 2023 Emerging Pharma Leaders: Natasha A. Hernday, chief business officer, Seagen; Simon Holland, vice president, women's health commercial lead, Organon; Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio; Frank Watanabe, president and CEO, Arcutis Biotherapeutics; and Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics. SPONSOR: APEX Awards https://www.pharmexec.com/apex-awards

Launching a drug and receiving approvals—whether it’s in the U.S. or globally—is challenging to navigate. It’s a process that often takes years and a lot of back-and-forth communication with regulatory bodies. In this episode, Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, discusses drug approvals and drug launches from a legal perspective, including 1) his work as an attorney; 2) tips for drug approvals from a legal perspective; 3) current regulatory challenges the industry is facing in the U.S.; 4) the shift away from a one-sized-fits all approach to marketing and global launches; 5) tips for companies navigating the regulatory landscape in the U.S.; 6) when to launch a drug in a country outside of the U.S.; and 7) drug pricing. Join Meg Rivers, managing editor, as she dives into this topic with Cope.

In this episode of the Pharmaceutical Executive Podcast, we dive into a conversation with Frank Watanabe, president and CEO of Arcutis, a medical dermatology company with a patient-first approach. Discover how Arcutis is transforming the dermatology landscape with its innovative product offerings, such as FDA-approved Zoryve for topical treatment of plaque psoriasis and their upcoming products for seborrheic dermatitis and atopic dermatitis. Learn about the company's guiding principles, the importance of keeping patients at the forefront of decision-making, and the need for further innovation in the dermatology sector after decades of stagnation.

Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, speaks with Meg Rivers, managing editor, about: 1) her journey into the world of pharma, including her transition from being a physician/surgeon to working in clinical trials; 2) both women’s and men’s reproductive health; 3) the latest technologies in fertility treatment (for men and women); 4) unmet needs in fertility care; 5) trends in contraception and fertility treatment; 6) DE&I and access to care, and 7) predictions for the contraception and fertility treatment spaces in the coming years

Two companies join forces to unlock the hidden potential in existing drugs to save lives suffering from rare diseases. In 2010, Dr. David Fajgenbaum, co-founder, Every Cure, was a third-year medical student when he became critically ill with Castleman disease (CD). After months of hospitalization and in critical condition, nearly dying several times, he launched an initiative to find treatments to save his life and others. Fajgenbaum and Michelle Longmire, CEO and co-founder, Medable—both physicians and entrepreneurs—team up in a new partnership to treat rare diseases by repurposing drugs that are already on the market and finding other therapeutic areas where these drugs can have an impact.

Cathi Ahearn is a seasoned biotechnology leaders with formative stints at Genentech, Roche, and now at Bristol Myers Squibb, as SVP of worldwide commercial portfolio strategy. Cathi is focused on one goal: shortening the path between creating medical innovation and getting that innovation to patients. Cathi chats with senior editor at Pharmaceutical Executive about her experiences in the past 20+ years and most importantly, the power of cross-functional collaboration, bringing different teams together and tearing down silos that limit the impact new innovations can have for patients.

Across most industries, finding and keeping the right talent is a constant challenge for companies. This challenge is perhaps even more prevalent in the pharmaceutical industry, which requires a significant amount of specialization. Rebekah Martin, senior VP of reward, inclusion, and talent acquisition for AstraZeneca, discusses recruiting talent in pharma with Meg Rivers, managing editor. Specifically, Martin talks about 1) her journey into pharma; 2) reasons that finding and keeping talent is a challenge today in pharma; 3) ways to address the need for talent; 4) identifying and nurturing young talent; 5) increasing interest in working in bio/pharma, particularly among students; 6) how talent can be nurtured; and 7)how the industry can support and encourage diversity in the workforce.

Join Tina Fascetti, CCO of The Agency Network at MJH Life Sciences for a podcast interview with Ryan Potter, ACD Art, and Priscila Ramos, ACD Copy, from McCann Health as they share the "behind the creative" story of their Apex Award-winning consumer creative campaign for Entresto. The Apex Awards is judged by none other than the people they are aimed to connect with, the patients themselves.

In his position, Faruk Capan leads thousands of employees around the globe with a focus on bold innovation—one can imagine how excited he is about Chat GPT, which set the record for fastest-growing user base in history. Senior editor Fran Pollaro and Faruk go back and forth about positives, negatives, hopes, and fears attached to generative AI for us as regular humans, and as pharma marketers. The pair delve into content creation, creative, video production, research, sales and marketing…it’s clear that we’re on the precipice of life-changing innovation.